A translational assessment of preclinical versus clinical tools for the measurement of cardiac contractility: Comparison of LV dP/dtmax with echocardiography in telemetry implanted beagle dogs

Journal of Pharmacological and Toxicological Methods

Volumn 69, Issue 1, 2014, Pages 17-23

  Cools, Frank ^a   Dhuyvetter, Deborah ^a   Vanlommel, Annik ^a   Janssens, Sigrid ^a   Borghys, Herman ^a   Geys, Helena ^a   Gallacher, David J ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Beagle dog; Contractility; Echocardiography; Ejection fraction; Fractional shortening; LV dP dtmax; LV dP dtmax P; Methods

Indexed keywords

ATENOLOL; CLONIDINE; ISOPRENALINE; MILRINONE; MINOXIDIL; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG DOSE COMPARISON; ECHOCARDIOGRAPHY; FEMALE; HEART CONTRACTION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; INTERMETHOD COMPARISON; NONHUMAN; TRANSLATIONAL RESEARCH;

BEAGLE DOG; C(MAX); CONTRACTILITY; CONTRACTILITY MEASURED AS THE MAXIMUM RAISE OF PRESSURE IN THE LEFT VENTRICLE; CONTRACTILITY MEASURED AS THE MAXIMUM RAISE OF PRESSURE IN THE LEFT VENTRICLE, CORRECTED FOR PRESSURE; ECHOCARDIOGRAPHY; EF; EJECTION FRACTION; FRACTIONAL SHORTENING; FS; LEFT VENTRICULAR PRESSURE; LV DP/DT(MAX); LV DP/DT(MAX)/P; LVP; M-MODE; MAXIMUM PLASMA CONCENTRATION; METHODS; MOTION MODE OF ECHO-CARDIOGRAPHY; T(MAX); TDP; TIME POINT OF MAXIMUM PLASMA CONCENTRATION; TORSADES DE POINTES;

ANIMALS; CARDIOTONIC AGENTS; DOGS; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART VENTRICLES; MYOCARDIAL CONTRACTION; TELEMETRY; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 84886696088     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.10.003     Document Type: Article

References (27)

1. Anon ICHS7A: Safety pharmacology studies for human pharmaceuticals (Accessed January 2013). http://private.ich.org/LOB/media/MEDIA504.pdf.
2. Arevalo J.V. Clonidine and left ventricular function in ten patients with essential hypertension. Journal of Cardiovascular Pharmacology 1986, 8(Suppl. 3):56-60.
3. Cools F., Janssens S., Vanlommel A., Teisman A., Towart R., Gallacher D.J. ECG arrhythmias in non-implanted vs. telemetry implanted dogs: Need for screening before and sufficient recovery time after implantation. Journal of Pharmacological and Toxicological Methods 2011, 64:60-67.
4. Curtis J.P., Sokol S.I., Wang Y., Rathore S.S., Ko D.T., Jadbabaie F., et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. Journal of the American College of Cardiology 2003, 42(4).
5. Frishman W.H., Sonnenblick E.H., Sica D.A. Cardiovascular pharmacotherapeutics, manual 2004, McGraw-Hill, Medical Publishing Division. 2nd ed.
6. Fung M., Thornton A., Mybeck K., Hsiao-Hui J., Hornbuckle K., Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets: 1960 to 1999. Drug Information Journal 2001, 35:293-315.
7. Gottdiener J.S., Bednarz J., Devereux R., Gardin J., Klein A., Manning W.J., et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. A report from the American society of echocardiography's guidelines and standards committee and the task force on echocardiography in clinical trials. Journal of the American Society of Echocardiography 2004, 17:1086-1119.
8. Hanton G., Eder V., Rochefort G., Bonnet P., Hyvelin J.-M. Echocardiography, a non-invasive method for the assessment of cardiac function and morphology in preclinical drug toxicology and safety pharmacology. Expert Opinion Drug Metabolism Toxicology 2008, 4(6):681-696.
9. Harrison M.R., Smith M.D., Nissen S.E., Grayburn P., Demaria A.N. Use of exercise Doppler echocardiography to evaluate cardiac drugs: Effects of propranolol and verapamil on aortic blood flow velocity and acceleration. Journal of the American College of Cardiology 1988, 11(5):1002-1009.
10. Jones B., Kenward M.G. Design and analysis of cross-over trials 2003, Chapmal and Hall/CRC, London. second ed.
11. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American College of Cardiology 2005, 18:1440-1463.
12. Laverty H.G., Benson C., Cartwright E.J., Cross M.J., Garland C., Hammond T., et al. Review. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. British Journal of Pharmacology 2011, 163:675-693.
13. Levy J.H., Bailey J.M., Deeb G.M. Intravenous milrinone in cardiac surgery. The Annals of Thoracic Surgery 2002, 73:325-330.
14. Markert M., Klumpp A., Trautmann T., Mayer K., Stubhan M., Guth B. The value added by measuring myocardial contractility 'in vivo' in safety pharmacological profiling of drug candidates. Journal of Pharmacological and Toxicological Methods 2007, 56:203-211.
15. max for changes in heart rate. Journal of Pharmacological and Toxicological Methods 2012, 66:98-105.
16. McDonagh T.A., Cunningham A.D., Morrison C.E., McMurray J.J.V., Ford I., Morton J.J., et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001, 86:21-26.
17. Meyer E.C., Sommers D.E.K., Avenant J.C. The effect of verapamil on cardiac sympathetic function. European Journal of Clinical Pharmacology 1991, 41:517-519.
18. Sarazan R.D., Kroehle J.P., Main B.W. Left ventricular pressure, contractility and dP/dtmax in nonclinical drug safety assessment studies. Journal of Pharmacological and Toxicological Methods 2012, 66:71-78.
19. Sarazan R.D., Mittelstadt S., Guth B., Koerner J., Zhang J., Pettit S. Cardiovascular function in Nonclinical drug safety assessment: Current issues and opportunities. International Journal of Toxicology 2011, 30(3):272-286.
20. Stoleru L., Wijns W., Van Eyll C., Bouvy T., Van Nueten L., Pouleur H. Effects of d-nebivolol and l-nebivolol on left ventricular systolic and diastolic function: comparison with d-l-nebivolol and atenolol. Journal of Cardiovascular Pharmacology 1993, 22(2):183-190.
21. Suga H., Sagawa K., Shoukas A.A. Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circulation Research 1973, 32(3):314-322.
22. Verbeke G., Molenberghs G. Linear mixed models for longitudinal data 2001, Springer, New York.
23. Vuille C., Weyman A. Left ventricle I: General considerations, assessment of chamber size and function. Principles and Practice of Echocardiography 1994, 2:575-624.
24. Wittelas R.M., Telli M. Underestimating cardiac toxicity in cancer trials: Lessons learned. Clinical Oncology 2012, 16:1916-1918.
25. Yeh E.T.H., Bickford C.L. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis and management. Journal of American College of Cardiology 2009, 53(24):2231-2247.
26. Yeh E.T.H., Tong A.T., Lenihan D.J., Yusus S.W., Swafford J., Champion C., et al. Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 2004, 109:3122-3131.
27. Zarghi A., Shafaati A., Foroutan S.M., Khoddam A. Rapid determination of minoxidil in human plasma using ion-pair HPLC. Journal of Pharmaceutical and Biomedical Analysis 2004, 36:377-379.